Santanu Ghosh

Santanu Ghosh

Auto-generated profile, based on publicly available information

Santanu Ghosh

Department of Biochemistry, University of Illinois at Urbana-Champaign, Urbana, IL, 61801, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 July 2023 in Cancer Research
Verified
Journal Article
Closed access
PDF file
SGSantanu Ghosh
Santanu Ghosh
RYRachel Yang
Rachel Yang
DDDarjan Duraki
Darjan Duraki
JZJunyao Zhu
Junyao Zhu
JKJi Eun Kim
Ji Eun Kim
DSDavid J. Shapiro
David J. Shapiro
Several emerging therapies kill cancer cells primarily by inducing necrosis. As necrosis activates immune cells, potentially, uncovering the molecular drivers of anticancer therapy–induced necrosis could reveal approaches for enhancing immunotherapy efficacy. To identify necrosis-associated genes, we performed a genome-wide CRISPR-Cas9 screen with negative selection against necrosis-inducing preclinical agents BHPI and conducted follow-on experiments with ErSO. The screen identified transient receptor potential melastatin member 4 (TRPM4), a calcium-activated, ATP-inhibited, sodium-selective plasma membrane channel. Cancer cells selected for resistance to BHPI and ErSO exhibited robust TRPM4 downregulation, and TRPM4 reexpression restored sensitivity to ErSO. Notably, TRPM4 knockout (TKO) abolished ErSO-induced regression of breast tumors in mice. Supporting a broad role for TRPM4 in necrosis, knockout of TRPM4 reversed cell death induced by four additional diverse necrosis-inducing cancer therapies. ErSO induced anticipatory unfolded protein response (a-UPR) hyperactivation, long-term necrotic cell death, and release of damage-associated molecular patterns that activated macrophages and increased monocyte migration, all of which was abolished by TKO. Furthermore, loss of TRPM4 suppressed the ErSO-induced increase in cell volume and depletion of ATP. These data suggest that ErSO triggers initial activation of the a-UPR but that it is TRPM4-mediated sodium influx and cell swelling, resulting in osmotic stress, which sustains and propagates lethal a-UPR hyperactivation. Thus, TRPM4 plays a pivotal role in sustaining lethal a-UPR hyperactivation that mediates the anticancer activity of diverse necrosis-inducing therapies. Significance: A genome-wide CRISPR screen reveals a pivotal role for TRPM4 in cell death and immune activation following treatment with diverse necrosis-inducing anticancer therapies, which could facilitate development of necrosis-based cancer immunotherapies.

29 April 2025 in Cancer Letters
Verified
Journal Article
Closed access
DDDarjan Duraki
Darjan Duraki
MUSARRAT JABEENMUSARRAT JABEEN
MUSARRAT JABEEN
CMChengjian Mao
Chengjian Mao
LWLawrence Wang
Lawrence Wang
SGSantanu Ghosh
Santanu Ghosh
DSDavid J. Shapiro
David J. Shapiro


31 July 2023
Verified
Other
Open access
SGSantanu Ghosh
Santanu Ghosh
RYRachel Yang
Rachel Yang
DDDarjan Duraki
Darjan Duraki
JZJunyao Zhu
Junyao Zhu
JKJi Eun Kim
Ji Eun Kim
DSDavid J. Shapiro
David J. Shapiro
Supplementary Data from Plasma Membrane Channel TRPM4 Mediates Immunogenic Therapy–Induced Necrosis

1 August 2023
Verified
Other
Open access
SGSantanu Ghosh
Santanu Ghosh
RYRachel Yang
Rachel Yang
DDDarjan Duraki
Darjan Duraki
JZJunyao Zhu
Junyao Zhu
JKJi Eun Kim
Ji Eun Kim
DSDavid J. Shapiro
David J. Shapiro
Supplementary Data from Plasma Membrane Channel TRPM4 Mediates Immunogenic Therapy–Induced Necrosis

31 July 2023
Verified
Other
Open access
SGSantanu Ghosh
Santanu Ghosh
RYRachel Yang
Rachel Yang
DDDarjan Duraki
Darjan Duraki
JZJunyao Zhu
Junyao Zhu
JKJi Eun Kim
Ji Eun Kim
DSDavid J. Shapiro
David J. Shapiro
Supplementary Data from Plasma Membrane Channel TRPM4 Mediates Immunogenic Therapy–Induced Necrosis